REGULATION OF ACETYLCHOLINE-RECEPTOR ALPHA-SUBUNIT VARIANTS IN HUMAN MYASTHENIA-GRAVIS - QUANTIFICATION OF STEADY-STATE LEVELS OF MESSENGER-RNA IN MUSCLE BIOPSY USING THE POLYMERASE CHAIN-REACTION

Citation
T. Guyon et al., REGULATION OF ACETYLCHOLINE-RECEPTOR ALPHA-SUBUNIT VARIANTS IN HUMAN MYASTHENIA-GRAVIS - QUANTIFICATION OF STEADY-STATE LEVELS OF MESSENGER-RNA IN MUSCLE BIOPSY USING THE POLYMERASE CHAIN-REACTION, The Journal of clinical investigation, 94(1), 1994, pp. 16-24
Citations number
48
Categorie Soggetti
Medicine, Research & Experimental
ISSN journal
00219738
Volume
94
Issue
1
Year of publication
1994
Pages
16 - 24
Database
ISI
SICI code
0021-9738(1994)94:1<16:ROAAVI>2.0.ZU;2-W
Abstract
Myasthenia gravis (MG) is an autoimmune disease mediated by auto-antib odies that attack the nicotinic acetylcholine receptor (AChR). To eluc idate the molecular mechanisms underlying the decrease in AChR levels at the neuromuscular junction, we investigated the regulation of AChR expression by analyzing mRNA of the two AChR alpha subunit isoforms (P 3A+ and P3A-) in muscle samples from myasthenic patients relative to c ontrols. We applied a quantitative method based on reverse transcripti on of total RNA followed by polymerase chain reaction (PCR), using an internal standard we constructed by site-directed mutagenesis. An incr eased expression of mRNA coding for the alpha subunit of the AChR isof orms was observed in severely affected patients (P < 0.003 versus cont rols) but not in moderately affected patients, independently of the an ti-AChR antibody titer. Study of mRNA precursor levels indicates a hig her expression in severely affected patients compared to controls, sug gesting an enhanced rate of transcription of the message coding for th e alpha subunit isoforms in these patients. We have also reported that mRNA encoding both isoforms are expressed at an approximate 1:1 ratio in controls and in patients. We have thus identified a new biological parameter correlated with disease severity, and provide evidence of a compensatory mechanism to balance the loss of AChR in human myastheni a gravis, which is probably triggered only above a certain degree of A ChR loss.